,Topics,Questions
0,A statement that the study involves research,"Which of the following statements is true regarding the nature of the study described in the consent form?
A) The study is a routine medical treatment, not a research study.
B) The study is a research study designed to evaluate a new treatment combination for malignant mesothelioma.
C) The study is a commercial product trial with no research components.
D) The study is a personal interview series without any medical or research procedures.

Correct answer: B) The study is a research study designed to evaluate a new treatment combination for malignant mesothelioma."
1,An explanation of the purposes of the research,"What is the primary goal of the research study described in the consent form?
A) To evaluate the effectiveness of a new physical therapy program for mesothelioma patients; B) To determine the best surgical techniques for mesothelioma treatment; C) To find a safe dose of LMB-100 in combination with ipilimumab for treating malignant mesothelioma; D) To test the efficacy of standard chemotherapy alone in mesothelioma patients

Correct answer: C"
2,The expected duration of the subject's participation,"What is the expected duration of a participant's involvement in the study?
A) Until the participant decides to withdraw; B) For a fixed period of 6 months; C) For the rest of the participant's life; D) For a duration of 1 year
Correct answer: C) For the rest of the participant's life"
3,Any additional costs to the subject that may result from participation in the research,"Which of the following statements is true regarding any additional costs you may incur as a result of participating in this study?
A) You will be responsible for all medical costs associated with the study.
B) The NIH will cover all costs, including travel and lodging, without any need for reimbursement.
C) You may have to pay for some tests and procedures performed outside the NIH Clinical Center.
D) Participation in this study will result in significant out-of-pocket expenses for all medical procedures.

Correct answer: C) You may have to pay for some tests and procedures performed outside the NIH Clinical Center."
4,A description of the procedures to be followed,"Which of the following statements accurately describes the procedure for administering LMB-100 in the study?

A) LMB-100 is administered orally once a day for the duration of the study.
B) LMB-100 is injected into the tumor(s) on days one and four of one 21-day cycle, requiring an approximately 8-day hospital stay each time.
C) LMB-100 is given as a continuous intravenous infusion over a period of 21 days without the need for hospitalization.
D) LMB-100 is self-administered by the patient at home with weekly check-ins at the study site.

Correct answer: B) LMB-100 is injected into the tumor(s) on days one and four of one 21-day cycle, requiring an approximately 8-day hospital stay each time."
5,The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject,"What should you expect if you choose to withdraw from the study at any time?
A) You will be required to pay for all study-related expenses incurred up to the point of withdrawal; B) You may be asked to undergo certain tests to ensure it is safe for you to stop the treatment; C) You will lose access to all medical services provided by the NIH; D) You will be obligated to continue participating in other unrelated studies.

Correct answer: B"
6,Identification of any procedures which are experimental,"Which of the following procedures is considered experimental in the context of this study?
A) Standard chemotherapy for malignant mesothelioma; B) Intratumor injection of LMB-100 combined with systemic administration of ipilimumab; C) Routine blood and urine tests; D) CT scans or MRIs to monitor tumor size

Correct answer: B"
7,The approximate number of subjects involved in the study,"How many participants are expected to be enrolled in the Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant Mesothelioma?
A) 10; B) 14; C) 20; D) 25
Correct answer: B"
8,A description of any reasonably foreseeable risks or discomforts to the subject,"Which of the following is a potential risk or discomfort associated with participating in the Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant Mesothelioma?
A) Temporary loss of hair color; B) Increased risk of common cold; C) Kidney damage that may require dialysis; D) Enhanced sense of taste

Correct answer: C) Kidney damage that may require dialysis"
9,A description of any benefits to the subject or to others which may reasonably be expected from the research,"Which of the following statements best describes the potential benefits of participating in the Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant Mesothelioma?
A) Participants will definitely experience a reduction in tumor size and symptoms.
B) Participants will receive financial compensation for the reduction of their tumor size.
C) Participants may potentially experience shrinking of their tumor or a decrease in symptoms caused by the cancer, although this is not guaranteed.
D) Participants will benefit from the study by receiving FDA-approved treatment for malignant mesothelioma.

Correct answer: C) Participants may potentially experience shrinking of their tumor or a decrease in symptoms caused by the cancer, although this is not guaranteed."
10,"A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject","What are the alternative treatment options available to you if you choose not to participate in the Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant Mesothelioma?
A) You can opt for a specialized surgical intervention not mentioned in the study; 
B) You can receive standard care treatments such as surgery, radiation, or FDA-approved drugs for your disease; 
C) There are no alternative treatments available outside of this study; 
D) You will be provided with a new experimental drug not yet approved by the FDA.

Correct answer: B"
11,"A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained","Which of the following entities may have access to your identifiable medical information during the study according to the confidentiality protections provided?
A) The study Sponsor, Center for Cancer Research, NCI, or their agents;
B) National Institutes of Health Intramural Institutional Review Board;
C) The NIH and other government agencies like the FDA;
D) All of the above;
E) None of the above.

Correct answer: D) All of the above;"
12,"For research involving more than minimal risk, an explanation as to whether any compensation, and an explanation as to whether any medical treatments are available, if injury occurs and, if so, what they consist of, or where further information may be obtained","If you experience an injury as a result of participating in this study, what kind of compensation or medical treatment can you expect to receive from the NIH?

A) The NIH will provide long-term medical care and financial compensation for research-related injuries.
B) The NIH will provide short-term medical care for any injury resulting from participation in research, but no long-term medical care or financial compensation.
C) The NIH will cover all medical and incidental costs related to the injury, including long-term care.
D) The NIH will provide financial compensation for any lost wages, pain, and suffering caused by research-related injuries.

Correct answer: B) The NIH will provide short-term medical care for any injury resulting from participation in research, but no long-term medical care or financial compensation."
13,"Research, Rights or Injury: An explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a research-related injury to the subject","If you experience a research-related injury during the study, whom should you contact for assistance?

A) The study sponsor's legal department; 
B) The Principal Investigator, Raffit Hassan, M.D.; 
C) The NIH Office of IRB Operations; 
D) Your personal health care provider.

Correct answer: B) The Principal Investigator, Raffit Hassan, M.D."
14,"A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and the subject may discontinue participation at any time without penalty or loss of benefits, to which the subject is otherwise entitled","What does the consent form state about your right to discontinue participation in the study?

A) You may discontinue at any time but will lose some benefits.
B) You may discontinue at any time without any impact on your entitled benefits.
C) Discontinuation is only allowed with prior approval from the study team.
D) If you discontinue, you will face a penalty as per the study's regulations.

Correct answer: B) You may discontinue at any time without any impact on your entitled benefits."
